MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is gearing up to showcase critical research at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled from October 29 to November 1, 2024, in Madrid, Spain. The company will present two scientific posters that highlight significant advancements in Alzheimer’s treatment.
Dr. Maria Maccecchini, President and CEO of Annovis Bio, will lead the presentations. The first poster, titled “Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer’s Patients,” will be available from October 29 to October 30. This presentation will explore the promising effects of Buntanetap in early-stage Alzheimer’s patients, with a particular focus on those carrying the APOE4 gene variant known to increase the risk of the disease.
The second poster, “Biomarker Data Showed Buntanetap Reduced Neurotoxic Proteins, Improved Axonal Integrity, Reduced Inflammation, and Neuronal Functions in Alzheimer’s Clinical Studies,” will be presented on October 31. This research provides insights into how Buntanetap can potentially mitigate neurotoxic damage and promote neuronal health, highlighting its therapeutic potential in addressing Alzheimer’s disease.
The CTAD conference is a pivotal event that convenes experts from pharmaceutical companies, academic institutions, and patient advocacy groups to share and discuss innovative strategies for Alzheimer’s treatment. This platform allows Annovis Bio to demonstrate its commitment to advancing research in neurodegenerative diseases.
The scientific posters will be accessible on Annovis Bio’s website after the conference, allowing a broader audience to review the company’s novel findings. This participation underscores the company’s ongoing dedication to combating Alzheimer’s through rigorous scientific exploration and innovation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.